Sigrid V Carlsson1, Monique J Roobol. 1. aMemorial Sloan Kettering Cancer Center, Departments of Surgery and Epidemiology & Biostatistics, New York, USA bInstitute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sweden cDepartment of Urology, Erasmus Medical Center, Rotterdam, The Netherlands.
Abstract
PURPOSE OF REVIEW: To provide an overview of the current state of the evidence and highlight recent advances in the evaluation and diagnosis of clinically significant prostate cancer, focusing on biomarkers, risk calculators and multiparametric MRI (mpMRI). RECENT FINDINGS: In 2017 there are numerous options to improve early detection as compared to a purely prostate-specific antigen (PSA)-based approach. All have strengths and drawbacks. In addition to repeating the PSA and performing clinical work-up (digital rectal examination and estimation of prostate volume), additional tests investigated in the initial biopsy setting are: %free PSA, Prostate Health Index, 4-kallikrein score, SelectMDx, and Michigan Prostate Score and in the repeat setting: %free PSA, Prostate Health Index, 4-kallikrein score, Prostate Cancer Antigen 3, and ConfirmMDx. Risk calculators are available for both biopsy settings and incorporate clinical data with, or without, biomarkers. mpMRI is an important diagnostic adjunct. SUMMARY: There are numerous tests available that can help increase the specificity of PSA, in the initial and repeat biopsy setting. All coincide with a small decrease in sensitivity of detecting high-grade cancer. Cost effectiveness is crucial. The way forward is a multivariable risk assessment on the basis of readily available clinical data, potentially with the addition of PSA subforms, preferably at low cost. MRI in the prediagnostic setting is promising, but is not ready for 'prime time'.
PURPOSE OF REVIEW: To provide an overview of the current state of the evidence and highlight recent advances in the evaluation and diagnosis of clinically significant prostate cancer, focusing on biomarkers, risk calculators and multiparametric MRI (mpMRI). RECENT FINDINGS: In 2017 there are numerous options to improve early detection as compared to a purely prostate-specific antigen (PSA)-based approach. All have strengths and drawbacks. In addition to repeating the PSA and performing clinical work-up (digital rectal examination and estimation of prostate volume), additional tests investigated in the initial biopsy setting are: %free PSA, Prostate Health Index, 4-kallikrein score, SelectMDx, and Michigan Prostate Score and in the repeat setting: %free PSA, Prostate Health Index, 4-kallikrein score, Prostate Cancer Antigen 3, and ConfirmMDx. Risk calculators are available for both biopsy settings and incorporate clinical data with, or without, biomarkers. mpMRI is an important diagnostic adjunct. SUMMARY: There are numerous tests available that can help increase the specificity of PSA, in the initial and repeat biopsy setting. All coincide with a small decrease in sensitivity of detecting high-grade cancer. Cost effectiveness is crucial. The way forward is a multivariable risk assessment on the basis of readily available clinical data, potentially with the addition of PSA subforms, preferably at low cost. MRI in the prediagnostic setting is promising, but is not ready for 'prime time'.
Authors: M Minhaj Siddiqui; Soroush Rais-Bahrami; Baris Turkbey; Arvin K George; Jason Rothwax; Nabeel Shakir; Chinonyerem Okoro; Dima Raskolnikov; Howard L Parnes; W Marston Linehan; Maria J Merino; Richard M Simon; Peter L Choyke; Bradford J Wood; Peter A Pinto Journal: JAMA Date: 2015-01-27 Impact factor: 56.272
Authors: Monique J Roobol; Heidi A van Vugt; Stacy Loeb; Xiaoye Zhu; Meelan Bul; Chris H Bangma; Arno G L J H van Leenders; Ewout W Steyerberg; Fritz H Schröder Journal: Eur Urol Date: 2011-11-15 Impact factor: 20.096
Authors: Rui Henrique; Carmen Jerónimo; Manuel R Teixeira; Mohammad O Hoque; André L Carvalho; Irene Pais; Franclim R Ribeiro; Jorge Oliveira; Carlos Lopes; David Sidransky Journal: Mol Cancer Res Date: 2006-01 Impact factor: 5.852
Authors: Sigrid V Carlsson; Tiago M de Carvalho; Monique J Roobol; Jonas Hugosson; Anssi Auvinen; Maciej Kwiatkowski; Arnauld Villers; Marco Zappa; Vera Nelen; Alvaro Páez; James A Eastham; Hans Lilja; Harry J de Koning; Andrew J Vickers; Eveline A M Heijnsdijk Journal: Cancer Date: 2016-07-26 Impact factor: 6.860
Authors: James A Eastham; Elyn Riedel; Peter T Scardino; Moshe Shike; Martin Fleisher; Arthur Schatzkin; Elaine Lanza; Lianne Latkany; Colin B Begg Journal: JAMA Date: 2003-05-28 Impact factor: 56.272
Authors: Allison H Feibus; Oliver Sartor; Krishnarao Moparty; Kevin Chagin; Michael W Kattan; Elisa Ledet; Justin Levy; Benjamin Lee; Raju Thomas; Jonathan L Silberstein Journal: J Urol Date: 2016-04-29 Impact factor: 7.450
Authors: Claire de la Calle; Dattatraya Patil; John T Wei; Douglas S Scherr; Lori Sokoll; Daniel W Chan; Javed Siddiqui; Juan Miguel Mosquera; Mark A Rubin; Martin G Sanda Journal: J Urol Date: 2015-01-28 Impact factor: 7.450
Authors: Maher Albitar; Wanlong Ma; Lars Lund; Ferras Albitar; Kevin Diep; Herbert A Fritsche; Neal Shore Journal: J Cancer Date: 2016-02-02 Impact factor: 4.207
Authors: Ilknur Bugan; Selma Kucuk; Zeynep Karagoz; Scott P Fraser; Handan Kaya; Andrew Dodson; Christopher S Foster; Seyhan Altun; Mustafa B A Djamgoz Journal: Prostate Cancer Prostatic Dis Date: 2019-03-20 Impact factor: 5.554
Authors: Gian Maria Busetto; Francesco Del Giudice; Martina Maggi; Ferdinando De Marco; Angelo Porreca; Isabella Sperduti; Fabio Massimo Magliocca; Stefano Salciccia; Benjamin I Chung; Ettore De Berardinis; Alessandro Sciarra Journal: World J Urol Date: 2020-07-17 Impact factor: 4.226
Authors: Martina Maggi; Francesco Del Giudice; Ugo G Falagario; Andrea Cocci; Giorgio Ivan Russo; Marina Di Mauro; Giuseppe Salvatore Sepe; Fabio Galasso; Rosario Leonardi; Gabriele Iacona; Peter R Carroll; Matthew R Cooperberg; Angelo Porreca; Matteo Ferro; Giuseppe Lucarelli; Daniela Terracciano; Luigi Cormio; Giuseppe Carrieri; Ettore De Berardinis; Alessandro Sciarra; Gian Maria Busetto Journal: Cancers (Basel) Date: 2021-04-23 Impact factor: 6.639